Currently, futibatinib is being compared to cisplatin and gemcitabine as a first-line treatment in the phase III trial of advanced CCA harboring FGFR2 gene rearrangements in the FOENIX-CCA3 trial [96]. Here, FGFR2 is linked to cholangiocarcinoma.